Attention Deficit Hyperactivity Disorder (ADHD) affects an estimated 7 million (11.4%) children in the United States aged 3–17 years, as reported in a national survey of parents conducted in 2022. Nearly 6 in 10 children diagnosed with ADHD experience moderate to severe symptoms. Disturbingly, approximately 2 million children with ADHD did not receive specialized treatment in 2022.

For ADHD Awareness Month 2024, we will delve into the most recent guidelines on ADHD assessment, evaluation diagnosis and treatment including the most recent guidelines from the Society for Developmental and Behavioral Pediatrics. Following the release of their guidelines, FIVE new medications have been approved by the FDA for ADHD treatment. This article will concentrate on the guidelines and the updates from the FDA that have recently been approved.

Part 1 – Current ADHD Guidelines

To start, here is a listing of the current ADHD guidelines in the US:

Part 2 – FDA Approvals Since the Most Recent Guidelines

The medications/therapies that have been approved by the FDA since the last ADHD clinical guideline published in February 2020:

  • AZSTARYS (serdexmethylphenidate and dexmethylphenidate)
    • Fda Approved on 3/2/21
    • Corium, LLC.
    • AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.

  • QELBREE® (viloxazine extended-release capsules)
    • Supernus Pharmaceuticals
    • Fda Approved on 4/2/21
    • Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

  • DYANAVEL® XR (amphetamine) 
    • Tris Pharma
    • Fda approved on 11/5/21
    • DYANAVEL XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

  • XELSTRYM™ (dextroamphetamine)
    • Noven Pharmaceuticals
    • FDA approved on 3/23/2022
    • XELSTRYM is a transdermal amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) for adults and pediatric patients 6 years and older.

  • ONYDA™ XR (clonidine hydrochloride)
    • Tris Pharma
    • FDA Approved on 5/29/2024
    • Onyda XR is a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients six years and older.

Thank you for dedicating your time to review the updated ADHD guidelines, along with the recent significant changes and FDA approvals that have transpired since their publication. We are eagerly anticipating the forthcoming release of ADHD guidelines tailored specifically for adults, and we are excited to share our insights through our upcoming blog posts.

Your feedback is invaluable to us, and we welcome any suggestions you may have for future topics to be addressed in our guideline series. Please do not hesitate to reach out to us with your ideas or inquiries.

Copyright © 2024 Guideline Central, All rights reserved.